



## **Curriculum Vitae**

**Prof. Dr. Stephan Bodis**

**2006 - 2022**

# Curriculum Vitae

Prof. Dr. Stephan Beat Bodis

## Personal Details

---

First Name, Last Name	Stephan Beat Bodis
Address	Weinbergstrasse 11b, 5430 Wettingen
Telephone	+41 56 426 15 15
Date of Birth	16 February 1958
Marital Status	married, 4 children
Nationality	Swiss
E-Mail-Address	<a href="mailto:s.bodis@bluewin.ch">s.bodis@bluewin.ch</a>

## Employer

---

UZH/RAO USZ, Zurich IT'IS Foundation, Zurich	EO ad personam President ITIS Foundation Board, Project advisor
---	--

## Professional Career

---

Sept. 2012 – today	Leading Physician, Department for Radiation Oncology, University Hospital Zurich (10%)
2004 – 2021	Head Physician, Radiation Oncology Centre KSA-KSB, Kantonsspital Aarau
2000 – 2003	Associate Physican, Radio-Oncology, University Hospital Zurich
1995 – 2003	Senior Physician, Radiation Oncology, University Hospital Zurich
1995	Senior Physician, Radiation Oncology, Brigham and Women's Hospital, Joint Center for Radiation Therapy, Harvard Medical School, Boston
1993 – 1995	Research Fellow, Dana Farber Cancer Institute, Pediatric Oncology, Boston and Massachusetts Institute of Technology, Cancer Research Center and Department of Biology, Cambridge MA
1991 – 1995	Resident in Radiation Oncology, Joint Center for Radiation Therapy, Harvard Medical School, Boston, USA
1991	Research Fellow, Department of Molecular Pharmacology, Institute Gustave Roussy, Paris
1989 – 1991	Clinical Fellow Medical Oncology, Institute Gustave Roussy, Paris

## Education

---

2000	Medical Specialist Medical Radiology/Radiation Oncology FMH
1995	American Board Certification in Radiology (Specialty Radiation Oncology)
1994	FLEX part I and II in Boston (US Medical License Examination)
1985 – 1995	Training Internal Medicine, Medical Oncology/Hematology and Radiation Oncology in Baden (1985-1987), Zurich (1987-1989), Paris (1989-1991), Boston (1991-1995)
1978 – 1984	Medical Studies University of Freiburg and University of Basel

## Academic Career

---

2019	Lecturer ETH Zurich
Sept. 2012 – today	Full Professor (Extraordinarius), University of Zurich, Member of Medical Faculty
Sept. 2004 – Aug. 2012	Assistant Professor, University of Zurich, Medical Faculty
Mar. 1998 – Aug. 2004	Lecturer, University of Zurich, Medical Faculty

## Direct Requests from International University Clinics including On-site Visits

---

2009	Professorship/Head Radiation Oncology, McGill University, Montréal, Kanada
2006	Professorship/Head Radiation Oncology, University of Bern (Inselspital) – Candidature withdrawn
2002	Professorship/Head Radiation Oncology, University of Groningen, The Netherlands
2002	Professorship/Head Radiation Oncology, University Auckland, New Zealand
2001	Professorship/Head Radiation Oncology, University of Vancouver, Canada

## Certification/Accreditation Institute of Radiation Oncology KSA

---

**DKG und Iso-Certifications** Oncology Center Kantonsspital Aarau and Tumor Center Kantonsspital Baden

**Neu Iso-Certification for Hyperthermia Center Kantonsspital Aarau**

Eusoma Brustzentrum KSA

USA-NRG Main Member: Largest Clinical Study Group in Radiation Oncology (USA)

## Advertising of third-party funding/Research Grants (amount of money > 1 Mio. CHF since 2013)

33.	2020	Hyperboost (EU Horizon 2020)	CHF 281.276
32.	2019	Forschungsrat KSA Hyperthermia for multi-modal treatment of cancer	CHF 45.000
31.	2018	Krebsliga Aargau Hyperthermia for multi-modal treatment of cancer	CHF 50.000
30.	2018	Meier-Birkel-Stiftung Hyperthermia for multi-modal treatment of cancer	CHF 25.000
29.	2017	Hugo und Elsa Isler-Fonds Hyperthermia for multi-modal treatment of cancer	CHF 165.000
28.	2016	Günther und Regine Kelm Foundation: Hyperthermia for multi-modal treatment of cancer	CHF 200.000
26.	2016	Research Grant KSA A systematic review and meta-analysis for hyperthermia with radiotherapy versus chemoradio-therapy in locally advanced cervical cancer	CHF 40.302
26.	2015	Varian: Workflow Kantonsspital Aarau Kantonsspital QA (Portal Dosimetry)	CHF 180.000
25.	2015	A randomised phase II study of hyperthermia with chemoradiation versus chemoradiation alone following neoadjuvant chemotherapy for locally advanced pancreas cancer (HEATPAC).	open
24.	2015	Research Grant KSA: “A Phase I/II study of Concurrent Hyperthermia and Proton Beam Radiotherapy in Primary and Recurrent Unresectable Soft Tissue Sarcoma (HYPROSAR)“	CHF 96.698
23.	2015	Marie-Louise from Muralt-Foundation for “Evaluation of heat shock protein levels in dogs with cancer and its response after combined thermoradiotherapy”	CHF 140.000
22.		Research Grant KSA: project improving pain and functionality by analgesic radiotherapy in patients with joint osteoarthritis, Epikondylitis Radialis /Ulnaris or Fasziitis Plantaris	CHF 63.854
21.	2011 – today	Research Grant KSA: A Phase IIB study, combined radio-chemotherapy and heat therapy according to TUR-B in patients with muscle invasive bladder cancer	CHF 219.500
20.	2011 – today	Oncosuisse Research Grant: Pilot study to assess the feasibility and toxicity of preoperative external beam radiotherapy for glioblastoma multiforme	

- |     |             |  |             |
|-----|-------------|--|-------------|
| 19. | 2005 – 2007 | Oncosuisse Research Grant: Tailored local and loco regional proton and / or photon radiotherapy in highly selected left sided breast cancer patients – pre-requisites for a clinical phase II study for 2007 | CHF 100.000 |
| 18. | 2004/2005   | Research Grant Swiss National Funds:<br>9 <sup>th</sup> international Wolfsberg Meeting, Travel Grant for selected scientist from Eastern Europe   |             |
| 17. | 2002 – 2015 | Swiss Cancer League<br>Financial Support for 6 <sup>th</sup> – 15 <sup>th</sup> intl. Wolfsberg Meeting  |             |
| 16. | 2002 – 2004 | Research Grant from EORTC and<br>Research Grant from Swiss Cancer League:<br>Inhibition of Angiogenesis and combination with ionizing radiation:<br>influence of the microenvironment and treatment sequence |             |
| 15. | 2000        | Swiss National Fund<br>4 <sup>th</sup> intl. Wolfsberg Meeting. Financial support in recognition of the scientific value of this meeting   |             |
| 14. | 1999 – 2001 | Research Grant from Swiss Cancer League:<br>Mechanisms of ionizing radiation induced cell death: The role of protein kinase C and ceramide in radiation-induced signaling towards cell death                 |             |
| 13. | 1999 – 2001 | Research Grant from Swiss Cancer League:<br>Concurrent radiation and PKC 412 for palliative cancer treatment:<br>A phase I dose escalation study   |             |
| 12. | 1999 – 2004 | Research Grant from Novartis Inc. (Basel): Tumor cell radiosensitization: Novel molecular targets and mechanisms   |             |
| 11. | 1998 – 1999 | Research Grant of Zurich and of Argovia Cancer League:<br>Drugs and pathways of p53 independent apoptosis to improve radiosensitivity  |             |
| 10. | 1997 – 1999 | Research Grant from Swiss National Fund:<br>Molecular aspects of cell cycle control and radioresistance: The role of cell cycle regulation and apoptosis induction in human squamous cell cancer             |             |
| 09. | 1997 – 1998 | Research Grant from Zurich Cancer League:<br>Molecular mechanisms of radioresistance: The role of cell cycle control and apoptosis induction in human squamous cell cancer                                   |             |
| 08. | 1996 – 1998 | Research Grant Baugarten-Foundation: Molecular mechanisms of radioresistance: The role of cell cycle control and apoptosis induction in human squamous cell cancer   |             |
| 07. | 1996 – 2003 | Research Collaboration with Novartis Inc., Basel:<br>Drugs and pathways of p53 independent apoptosis to improve radiosensitivity   |             |

06. 1996 – 1997 Research Grant der Sassella Foundation Switzerland:  
Drugs and pathways of p53 independent apoptosis to improve radiosensitivity
05. 1996 – 1998 Research Grant from Swiss Cancer League:  
Drugs and pathways of p53 independent apoptosis to improve radiosensitivity
04. 1993/1994 Grant Swiss Cancer League/“Swiss NCI”
03. 1993 US Glaxo Research Grant:  
“Antiemetic therapy (Ondansetron vs. Prochlorperazine) in patients undergoing radiosurgery to CNS”
02. 1991/1992 Grant of Swiss National Fund for Supporting of Academic Talents (“Swiss NIH”)
01. 1990/1991 Contract de recherche clinique, Institut Gustave Roussy (Grant to study MDR1 expression in NHL using a xenograft nude mouse model and development of a clinical protocol using agents to overcome multidrug-resistance)

## Teaching Activities

---

### Undergraduate

- Medical Faculty, University of Zurich  
5015 Clinical Studies in Radio-Oncology (1h/semester)  
8030 Internship and Tutorial Radio-Oncology (2h/semester)  
Modul Palliative Care/Oncology (2h/semester)
- Natural Science Faculty University of Zurich  
Biology of Cancer Treatment «Old and Novel Therapeutic Strategies»  
BIO433 Lecture (2h/year)
- ETH Zürich: Physical examinations skills
- Kantonsspital Aarau: KSA summerschool (2h/year) for Swiss medical master students / bachelor students

### Postgraduate

- Postgraduate Teaching, Radiation Oncology Centre KSA-KSB (1x/week)
- Postgraduate Seminar, Radiation Oncology Centre KSA-KSB (1x/week)
- Postgraduate Teaching Courses/Workshops on national and international stage (Swiss Academy of Oncology, SASRO, SRO, ESTRO)
- Tumorboards (interdisciplinary Tumorboards at KS Aarau, KS Baden, KS Olten, PSI and USZ)

## Research Interest

---

- Oncology Hyperthermia (Technology, Biology, Clinical Trials)
- Combined Treatment Methods (Radiotherapy)
- Moleculare Mechanisms (clinical studies)
- Economics in Radiation Oncology / performance audit of radiation oncology
- Workflow / Improvements within radiation oncology

## Membership in Scientific Associations (selection)

---

- ASTRO (American Society of Therapeutic Radiation Oncology)
- EORTC (European Organisation for Research and Treatment of Cancer)
- ESHO (European Society of Hyperthermic Oncology)
- ESTRO (European Society of Radiation Oncology)
- FMH (Medical Society of Switzerland)
- PCG (Proton Collaboration Group Inc., USA)
- RTOG (Radiotherapy Oncology Group)
- SAKK (Swiss Society of Clinical Cancer Research)
- SAMO (Swiss Academy of Multidisciplinary Oncology)
- SASRO (Swiss Association of Scientific Radiation Oncology)
- SGSMP (Swiss Society of Radiobiology and Medical Physics)
- SRO (Swiss Society of Radiation Oncology)

## Membership Boards, Councils, Foundations (selected)

---

- ThermoTherapy Leadership Council (Intl. Hyperthermia Academic Societies and Industry; 2021-today): President
- IT'IS Foundation Board, Zurich, Switzerland (2014 - today): President
- Fond d'action, University of Lausanne, Switzerland
- Foundation for Clinical Cancer **Research Switzerland**
- Research Foundation Canton Hospital Aarau

## Executive Positions in National and International Scientific Organisations (selected)

---

NRG (RTOG) USA	Co-Chair of the International Member Group (2013 – 2020)
EORTC	Member of protocol expert committee (PRC) of EORTC (2004 – 2020)
ESHO	Board Member 2011 – 2013 Award Komitee 2016 –
ESTRO	<ul style="list-style-type: none"><li>• Member of Radio Biology Committee ESTRO (1998 – 2004)</li><li>• Member of Internet Group ESTRO (1999 – 2004)</li><li>• ESTRO –Board Member (Councilor) (2001 – 2004)</li><li>• Member of the Clinical Committee (2007 – 2011)</li> <li>• ESTRO Meetings 1998 – 2010: Member of the Scientific and Program Committee</li></ul>
SAKK	<ul style="list-style-type: none"><li>• Oncosuisse/Swiss Cancer League, (2000 – 2007)</li><li>• President of the Radiation Oncology Group SAKK (2001 – 2007)</li><li>• SAKK Board Member (2007 – 2015)</li></ul>
SASRO	<ul style="list-style-type: none"><li>• Member of SASRO Board (Swiss Association of Scientific Radiation Oncology) (1997 – 2003; 2006 - 2012)</li><li>• SASRO Secretary 1997 – 2001)</li><li>• Vice President (2008 - 2012)</li></ul>

## Organisation of National and International Congresses (selected)

---

2017/ 2018	White Nights – Russian Annual Oncology Meeting (St. Petersburg) Program Committee Member
2017/ 2018	Program Committee ESHO 2017/ 2018
1997 – 2017	1st to 15th International Wolfsberg Meeting in Molecular Radiation Biology/ Oncology: Co-Organisator
2015	Co-President ESHO 2015 Zurich/Aarau
2010	Member of Program Committee ESTRO 2010 (Barcelona)
2008	Member of Program Committee ESTRO 2008 (Goteborg)
2007	Congress President 11 SASRO-Annual Meeting (Aarau)
2006	Member of Program Committee ESTRO 2006 (Dresden)
2006	Member of Scientific Committee ICTR (International Conference of translational research), Lugano
2004	Congress President ESTRO 2004 (Amsterdam)
2002	Congress Co-President of SASRO-Annual Meeting (Zurich)
2002	Member of Program Committee ESTRO 2002 (Prague)
2000	Member of Scientific Committee ESTRO 2000 (Istanbul)
1998	Member of Scientific Committee ESTRO 1998 (Edinburgh)

## Editorial Boards/Advisory boards

---

2013 - 2021	info@Onkologie
2008 - 2015	Strahlentherapie und Onkologie, Scientific Advisory Board
2005 - 2021	“Leading Opinions Hematology and Oncology” (scientific advisor/wissenschaftlicher Beirat)
2003 - 2015	“Radiotherapy and Oncology” (Editor: elected 09/2002)

## Awards and Prizes (selected)

- SASRO 2021: Honorary Member
- ESHO Pyrexar Award, New Orleans 2016
- Travel Award from American Society of Hematology, ASH 1996
- Travel Award from American Society of Therapeutic Radiation Oncology, ASTRO 1997
- Marquis Who's Who in Medicine and Healthcare, (1999 - ), Personal Biography included



### Journals (selected)

- British Journal of Cancer
- Cancer
- Cancers
- European Journal of Cancer
- Intl Journal Radiation Oncology Biology Physics
- Radiotherapy and Oncology
- Strahlentherapie und Onkologie

### Grants

- CRC - Cancer Research Campaign (UK): Clinical and Basic Research
- EORTC clinical protocols (Member Protocol review committee EORTC)
- EORTC translational research group (external expert)
- National Science Foundation, USA

## Publications

---

**2022**

116. **Machine Learning for the Detection and Segmentation of Benign Tumors of the Central Nervous System: A Systematic Review**  
Paul Windisch, Carole Köchli, Susanne Rogers, Christina Schröder, Robert Förster, Daniel R. Zwahlen, Stephan Bodis  
Cancers 2022, 14, 2676  
DOI: 10.3390/cancers 14112676
115. **Present Practice and Radiative Deep Hyperthermia in Combination with Radiotherapy in Switzerland**  
Emanuel Stutz, Emsad Puric, Adela Ademaj, Arnaud Künzi, Reinhardt Krcek, Olaf Timm, Dietmar Marder, Markus Notter, Susanne Rogers, Stephan Bodis, Oliver Riesterer  
Cancers 2022, 14, 1175  
PMID: 35267486 PMCID: PMC8909523 DOI: 10.3390/cancers14051175
114. **Oncologic Thermoradiotherapy: Need for Evidence, Harmonisation, and Innovation**  
S Bodis, P Ghadjar, G van Rhoon  
Cancers 2022, 14, 2418  
DOI: 10.3390/cancers14102418
113. **Hyperthermia: A Potential Game-Changer in the Management of Cancers in Low-Middle-Income Group Countries**  
Niloy R. Datta, Bharati M. Jain, Zatin Mathi, Sneha Datta, Satyendra Johari, Ashok R. Singh, Pallavi Kalbande, Pournima Kale, Vitaladevuni Shivkumar, and Stephan Bodis  
Cancers 2022, 14, 315  
DOI: 10.3390/cancers14020315
112. **Clinical Evidence for Thermometric Parameters to Guide Hyperthermia Treatment**  
Adela Ademaj, Danai P Veltsista, Pirus Ghadjar, Dietmar Marder, Eva Oberacker, Oliver J Ott, Peter Wust, Emsad Puric, Roger A Hälgl, Susanne Rogers, Stephan Bodis, Rainer Fietkau, Hans Crezee, Oliver Riesterer

**2021**

111. **Successful salvage of recurrent leptomeningeal disease in large cell neuroendocrine lung cancer with stereotactic radiotherapy**  
Seok-Yun Lee, Nicoletta Lomax, Sven Berkmann, Kathrin Vollmer, Oliver Riesterer, Stephan Bodis, Susanne Rogers  
Strahlentherapie und Onkologie 2021,  
PMID: 34459938 DOI: 10.1007/s00066-021-01814-0
110. **Feasibility of Temperature Control by Electrical Impedance Tomography in Hyperthermia**  
Redi Poni, Esra Neufeld, Myles Capstick, Stephan Bodis, Theodoros Samaras, Niels Kuster  
Cancers 2021, 13, 3297  
PMID: 34209300 PMCID: PMC8268554 DOI: 10.3390/cancers13133297
109. **The addition of deep hyperthermia to gemcitabine-based chemoradiation may achieve enhanced survival in unresectable locally advanced adenocarcinoma of the pancreas**  
S.J. Rogers, Nr. Datta, E.Puric, O.Timm, D. Marder, S. Khan, C.Mamot, J.Knuchel, A. Siebenhüner, B. Pestalozzi, M. Guckenberger, S. Bodis, O.Riesterer  
Clinical and Translational Radiation Oncology 2021, 27, 109-113
108. **In Reply to Roussakow**  
Niloy R Datta, Emanuel Stutz, Silvia Gomez, Stephan Bodis  
Intl. J. Radiat. Biol. Phys. 2021  
PMID: 33422281 DOI: 10.1016/j.ijrobp.2020.09.012
- 2020**
107. **A national survey on radiation oncology patterns of practice in Switzerland during the COVID-19 pandemic: Present changes and future perspectives**  
Vérane Achard, Daniel M Aebbersold, Abdelkarim S Allal, Nicolaus Andratschke, Brigitta G Baumert, Karl T Beer, Michael Betz, Thomas Breuneval, Stephan Bodis, Bernardino de Bari , Robert Förster, Alessandra Franzetti-Pellanda, Matthias Guckenberger, Evelyn Herrmann, Constance Huck, Kaouthar Khanfir, Oscar Matzinger, Nicolas Peguret, Gianfranco Pesce, Paul M Putora, Christiane Reuter, Antonella Richetti, Hansjörg Vees, Conny Vrieling, Kathrin Zaugg, Frank Zimmermann, Daniel R Zwahlen, Pelagia Tsoutsou, Thomas Zilli  
Radiotherapy and Oncology 2020, 150, 1-3  
PMID: 32512075 PMCID: PMC7274968 DOI: 10.1016/j.radonc.2020.05.047
106. **Prospective evaluation of changes in pain levels, quality of life and functionality after low dose radiotherapy for epicondylitis, plantar fasciitis, and finger**  
Susanne Rogers, Brigitte Eberle, Deborah R Vogt, Elisabeth Meier, Lorenz Moser, Silvia Gomez Ordoñez, Susanne Desborough, Oliver Riesterer, Istvan Takacs, Paul Hasler, Stephan Bodis  
Frontiers in Medicine, 2020, 7, 195  
PMID: 32509794 PMCID: PMC7249275 DOI: 10.3389/fmed.2020.00195
105. **Integrating loco-regional hyperthermia into the current oncology practice: SWOT and TOWS analyses**  
Niloy R Datta, H Petra Kok, Hans Crezee, Udo S Gaipl, Stephan Bodis  
Front. Oncol. 2020, 10, 819  
PMID: 32596144 PMCID: PMC7303270 DOI: 10.3389/fonc.2020.00819

2019

104. **Early results and volumetric analysis after spot-scanning proton therapy with concomitant hyperthermia in large inoperable sacral chordomas**  
Sebastien Tran, Emsad Puric, Marc Walser, Robert Poel, Niloy Ranjan Datta, Juerg Heuberger, Alessia Pica, Dietmar Marder, Nicoletta Lomax, Alessandra Bolsi, Petra Morach, Barbara Bachtiry, Beatrice M Seddon, Ralf Schneider, Stephan Bodis, Damien C Weber  
Br J Radiology 2019  
PMID: 30943055 PMCID: PMC7066944 DOI: 10.1259/bjr.20180883
103. **Perfusion CT radiomics as potential prognostic biomarker in head and neck squamous cell carcinoma.**  
Bogowicz M, Tanadini-Lang S, Veit-Haibach P, Pruschy M, Bender S, Sharma A, Hullner M, Studer G, Stieb S, Hemmatazad H, Glatz S, Guckenberger M, Riesterer O:  
Acta Oncol 2019, 58(10):1514-1518. IF 3.2
102. **Hyperthermia with photon radiotherapy is thermoradiobiologically analogous to neutrons for tumors without enhanced normal tissue toxicity**  
Datta NR, Bodis S  
Intl J Hyperthermia 2019, 36, 1, 1073-1078
101. **A pilot study of Radiotherapy and local Hyperthermia in elderly patients with muscle-invasive Bladder Cancers unfit for definitive surgery or Chemoradiotherapy**  
Datta NR, Stutz E, Puric E, Eberle B, Meister A, Marder D, Timm O, Rogers S, Wyler S, Bodis S  
Front Oncology 2019, 9, 889
100. **Challenges and Opportunities to Realize “The 2030 Agenda for sustainable Development” By the united nations: Implications for Radiation Therapy Infrastructure in low- and middle-income Countries**  
Datta NR, Rogers S, Bodis S  
Int J Radiat Oncol Biol Phys. 2019
99. **Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial.**  
Riesterer O, Ciernik IF, Stahel RA, Xyrafas A, Aebersold DM, Plasswilm L, Mahmut Ozsahin E, Zwahlen DR, Nackaerts K, Zimmermann F, Sabrina Stark L, Weder W, Krayenbuehl J, Swiss Group for Clinical Cancer R:  
Radiother Oncol 2019, 138:121-125. IF 5.2
98. **Hyperthermia with radiotherapy reduces tumour alpha/beta: Insights from trials of thermoradiotherapy vs. radiotherapy alone**  
Niloy R. Datta, Stephan Bodis  
Radiotherapy and Oncology, 2019, 138, 1-8
97. **Dependency of the blood oxygen level dependent-response to hyperoxic challenges on the order of gas administration in intracranial**

Stieb S, Riesterer O, Boss A, Weiss T, Guckenberger M, Ozbay PS, Nanz D, Rossi C: malignancies. *Neuroradiology* 2019, 61(7):783-793. IF 2.5

96. **Early results and volumetric analysis after spot-scanning proton therapy with concomitant hyperthermia in large inoperable sacral chordomas.**  
Tran S, Puric E, Walser M, Poel R, Datta NR, Heuberger J, Pica A, Marder D, Lomax N, Bolsi A, Morach P, Bachtary B, Seddon BM, Schneider R, Bodis S, Weber DC  
*Brit J Radiol* 2019, 92

95. **Radiotherapy for melanoma: more than DNA damage.**  
*Dermatol Res Pract* 2019, Article ID 9435389,  
Rogers S, Puric, E, Eberle B, Datta NR, Bodis S.

#### 2018

94. **Efficacy and safety evaluation of the various therapeutic options in locally advanced cervix cancer: A systematic review and network meta-analysis of randomized clinical trials.** Datta NR, Stutz E, Gomez S, Bodis S.  
*Int J Radiat Oncol Biol Phys* 2018, 103: 411-437

93. **Swiss hyperthermia clinical and research activities: integrating with radiation therapy**  
*Swiss Cancer Bulletin* 2018,3: 249-252  
Datta NR, Puric E, Bodis S.

92. **Ein praxisbezogener Überblick, Info Onkologie & Hämatologie 2018**  
6: 35-39  
Stutz E, Steinauer K, Puric E, Datta NR, Bodis S.

91. **Clinical estimation of alpha/beta values for prostate cancer from isoeffective phase III randomized trials with moderately hypofractionated radiotherapy.**  
*Acta Oncol* 2018,57: 883-894.  
Datta NR, Stutz E, Rogers S, Bodis S.

#### 2017

90. **Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer.**  
Pirus Ghadjar, Stefanie Hayoz, Vera Genitsch, Daniel R Zwahlen, Tobias Hölscher, Philipp Gut, Matthias Guckenberger, Guido Hildebrandt, Arndt-Christian Müller, Paul M Putora, Alexandros Papachristofilou, Lukas Stalder, Christine Biaggi-Rudolf, Marcin Sumila, Helmut Kranzbühler, Yousef Najafi, Piet Ost, Ngwa C Azinwi, Christiane Reuter, Stephan Bodis, Kaouthar Khanfir, Volker Budach, Daniel M Aebersold, George N Thalmann  
*BJUI*, November 2017, Pages E45-E51

89. **"HEATPAC" - A phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer.**  
N.R. Datta, B. Pestalozzi, PA Clavien, A. Siebenhüner, E. Puric, S. Khan, C. Mamot, O. Riesterer, J. Knuchel, CS. Reiner, S. Bodis  
*Radiotherapy & Oncology*, November 2017,12:183

88. **Conventional versus hypofractionated radiotherapy in localized or locally**

**advanced prostate cancer: A systematic review and metaanalysis along with therapeutic implications**

N. R. Datta, E. Stutz, S. Rogers, S. Bodis

Radiotherapy & Oncology, November 2017, Volume 99, Issue 3, Pages 573-589

87. **Novel hyperthermia applicator system allows adaptive treatment planning: Preliminary clinical results in tumor-bearing animals**  
S. Dressel, M.-C. Gosselin, Myles Cpastick, C. Rohrer Bley, S. Bodis [+5]  
Veterinary and Comparative Oncology, September 2017
86. **Molecular radiation biology/oncology and its impact on preclinical and clinical research in radiotherapy**  
H. Peter Rodemann, Niloy Ranjan Datta, Stephan Bodis  
Radiotherapy & Oncology, September 2017, Volume 124, Issue 3, Pages 339-343
85. **Preoperative or Postoperative Radiosurgery for Brain Metastases?**  
B.Eberle, S. Rogers, N. Lomax, S. Bodis, J. Fandino, [+ 4]  
Thieme, Journal of Neurological Surgery, Jun 2017; 78(S 01): S1-S22
84. **OC-0125: Relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 trial**  
Pirus Ghadjar, Stephan Bodis, Matthias Guckenberger, [+ 22]  
Radiotherapy & Oncology, May 2017 Volume 123, Supplement 1, Pages S58–S59
83. **OC-0036: Does androgen deprivation therapy result in lowering the alpha / beta values in prostate cancers?**  
Niloy Ranjan Datta, Stephan Bodis, Susanne Rogers, Emanuel Stutz  
Radiotherapy & Oncology May 2017 Volume 123, Supplement 1, Pages S13–S14
82. **PO-0710: Concurrent chemoradiotherapy in locally advanced cancer cervix: Systematic review and meta-analysis**  
N.R. Datta, S. Bodis, E. Stutz, [+ 4]  
Radiotherapy & Oncology, May 2017 Volume 123, Supplement 1, Page S372
81. **Concurrent chemoradiotherapy vs. radiotherapy alone in locally advanced cervix cancer: A systematic review and meta-analysis**  
Niloy Ranjan Datta, Stephan Bodis, Emanuel Stutz, Michael Liu  
National Center for Biotechnology Information, Gynecologic Oncology Volume 145, Issue 2, May 2017, Pages 374-385
80. **Locally advanced cancer cervix: a systematic review and metaanalysis of 17 randomized trials to explore the therapeutic evidence for concurrent chemoradiotherapy over radiotherapy alone**  
Niloy Ranjan Datta, Stephan Bodis, Susanne Rogers, Emanuel Stutz, D. Klingenbiel, Alexander Siebenhüner  
European Journal of Cancer, February 2017 Volume 72, Supplement 1, Page S89
- 2016**
79. **Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer**  
Pirus Ghadjar, Daniel Zwahlen, Matthias Guckenberger, Stephan Bodis, [+ 20]  
BJU International Journal, Dez. 2016

78. **Magnetic nanoparticle-induced hyperthermia with appropriate payloads: Paul Ehrlich's "magic (nano) bullet" for cancer theranostics?**  
N. R. Datta, S. Krishnan, D. E. Speiser [...] S. Bodis  
Cancer Treatment Reviews, Nov 2016, Volume 50, Pages 217–227
77. **Proton Irradiation with Hyperthermia in Unresectable Soft Tissue Sarcoma**  
Niloy Ranjan Datta, Ralf Schneider, Damien Charles Weber, Stephan Bodis, Emsad Puric, Dietmar Marder, Frank, Ahlhelm  
International Journal of Particle Therapy, Fall 2016, Vol. 3, No. 2, pp. 327-336.
76. **Radiotherapy infrastructure and human resources in Switzerland: Present status and projected computations for 2020**  
Niloy Ranjan Datta, Shaka Khan, Dietmar Marder [...] Stephan Bodis  
Strahlentherapie und Onkologie, September 2016, Volume 192, Issue 9, pp 599–608
75. **Hyperthermia and radiotherapy with or without chemotherapy in locally advanced cervical cancer: A systematic review with conventional and network meta-analyses**  
Niloy R. Datta, Susanne Rogers, Dirk Klingbiel · [...] · Stephan Bodis  
International Journal of Hyperthermia, Jul 2016, Volume 32, 2016 - Issue 7
74. **Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers: Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94)**  
Pirus Ghadjar, Christoph Pöttgen, Daniela Joos, Volker Budach, Stephan Bodis  
Strahlentherapie und Onkologie, August 2016, Volume 192, Issue 8, pp 552–560
73. **Hyperthermia and radiotherapy in loco-regional recurrent breast cancers: A systematic review and meta-analysis**  
Niloy R. Datta, Emsad Puric, Dirk Klingbiel, Stephan Bodis  
International journal of radiation oncology, biology, physics, April 2016, Volume 94, Issue 5, Pages 1073–1087
72. **A roadmap and cost implications of establishing comprehensive cancer care using a teleradiotherapy network in a group of sub-Saharan African countries with no access to radiotherapy**  
Niloy R. Datta, Michael Heuser, Stephan Bodis  
International journal of radiation oncology, biology, physics, Volume 95, Issue 5, 1 August 2016, Pages 1334-1343 2016
71. **Hyperthermia and radiotherapy in the management of head and neck cancers: A systematic review and meta-analysis.**  
Niloy R Datta, Susanne Rogers, Silvia Gómez Ordóñez, Emsad Puric, Stephan Bodis  
Volume 32, 2016 Pages 31-40, - Issue 1: 30th Annual Meeting of the European Society for Hyperthermic Oncology 2015  
Published on 16 Nov 2016
70. **Is hyperthermia combined with radiotherapy adequate in elderly patients with muscle-invasive bladder cancers? Thermo-radiobiological implications from an audit of initial results.**  
Niloy R Datta, Brigitte Eberle, Emsad Puric, Andreas Meister, Dietmar Marder, Olaf Timm, Anton Klimov, Stephan Bodis  
Volume 32, 2016 Pages 390-397 - Issue 4: The Use of Hyperthermia in the Treatment of Bladder Cancer, published on 22 Jan 2016

69. **Introduction to the special issue dedicated to the 30th Annual Meeting of the European Society for Hyperthermic Oncology – ESHO 2015**  
Davnah Payne, Stephan Bodis, Niels Kuster  
Volume 32, 2016 - Issue 1: 30th Annual Meeting of the European Society for Hyperthermic Oncology 2015
- 2015**
68. **Hyperthermia and radiotherapy in the management of head and neck cancers: A systematic review and meta-analysis**  
Niloy R. Datta, Susanne Rogers, Silvia Gómez Ordóñez, Stephan Bodis  
International Journal of Hyperthermia, Nov 2015
67. **Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10**  
Pirus Ghadjar, Stefanie Hayoz, Jürg Bernhard, Daniel M Aebbersold, Stephan Bodis  
Journal of Clinical Oncology 33(35), Nov 2015
66. **Hyperthermia-related clinical trials on cancer treatment within the ClinicalTrials.gov registry**  
Nikola Cihoric, Alexandros Tsikkinis, Gerard van Rhoon, Pirus Ghadjar, Stephan Bodis  
International Journal of Hyperthermia 31(6):1-6, May 2015
65. **Re-irradiation with hyperthermia for loco-regional recurrent breast cancer: A systematic review and meta-analysis**  
N.R. Datta, E. Puric, D. Klingbiel, S. Bodis  
Strahlentherapie und Onkologie, Apr 2015
64. **Radiation therapy for non-small cell cancer lung: Current concepts**  
Datta, N.R. Ordonez SG, Bodis S.  
InfoOnkologie & Heamotologie 2015: 3; 6-12
63. **Hyperthermia and re-irradiation for loco-regional recurrences in pre-irradiated breast cancers: A single institutional experience**  
Datta, N.R., Puric E., Heuberger J., Marder D., Lomax N., Timm, O., Memminger, P., Bodis, S.  
Swiss Med Weekly, 2015, 145:w14133
62. **Applications and Feasibility for Providing Cost-Effective Comprehensive Radiotherapy Care in Low- and Middle-Income Group Countries for Cancer Patients**  
Datta, N.R., Heuser M., Samiei M., Shah R., Lutters G., Bodis S.  
Tele-medicine and e Health 2015: 21: 523-532
61. **Are State-Sponsored New Radiation Therapy Facilities Economically Viable in Low- and Middle-Income Countries?**  
Datta, N.R., Samiei M., Bodis S.  
Int J Radiat Oncol Biol Phys, 2015; Volume 93, Issue 2, Pages 229–240
60. **Hyperthermia and Proton Irradiation in Unresectable Soft Tissue Sarcoma First Results from “HYPROSAR” Study (in Polish)**  
Datta N.R., Puric E, Schneider R., Weber DC., Marder D., Studer G., Fuchs B., Bodis S.:

59. **Are new radiation therapy facilities economically viable in low-and middle-income countries?**  
(N.R. Datta, M. Samiei, S. Bodis)  
Int J Radiat Oncol Biol Phys, Oktober 2015, Volume 93, Issue 2, Pages 229–240
58. **Enhanced tumour regression in a patient of liposarcoma treated with radiotherapy and hyperthermia: Evidence for dynamic immunomodulation by hyperthermia**  
(N.R. Datta, R. Grobholz, E. Puric, B. Bode, S. Khan, N. Lomax, U.S. Gaipl, B. Fuchs, S. Bodis)  
Int J Hyperthermia 2015, DOI: 10.3109/02656736.2015.1033482
57. **Local hyperthermia combined with radiotherapy and-/ or chemotherapy: Recent advances and promises for the future**  
N.R. Datta, S. Gómez Ordóñez, U.S. Gaipl, M.M. Paulides, H. Crezee, J. Gellermann, D. Marder, E. Puric, S. Bodis  
Cancer Treatment Reviews 2015
56. **Teleradiotherapy network: Applications and feasibility for providing cost effective comprehensive radiotherapy care in low-and middle-income group countries for cancer patients.**  
(N. R. Datta, M. Heuser, M. Samiei, R. Shah, Lutters G, S. Bodis)  
Telemed and e Health 2015; 21: 523-532.
55. **Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review.**  
Simon Zuber, Susan Weiss, Dieter Baaske, Michael Schöpe, Simon Stevens, Stephan Bodis, Daniel R Zwahlen  
Radiation oncology (London, England)  
Published on 16 Apr 2015 , doi:10.1186/s13014-015-0349-0
54. **Local hyperthermia combined with radiotherapy and-/or chemotherapy: Recent advances and promises for the future**  
N. R. Datta, S. Gómez Ordóñez, U. S. Gaipl, M. M. Paulides, H. Crezee, J. Gellermann, D. Marder, E. Puric, S. Bodis  
Cancer Treatment Reviews  
Published on 21 Mar 2015 , November 2015 Volume 41, Issue 9, Pages 742–753
53. **Cutting-edge research in basic and translational radiation biology/oncology reflections from the 14th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology 2015**  
H. Peter Rodemann, Stephan Bodis  
Radiotherapy and Oncology  
Published on 01 Jan 2015, Volume 116, Issue 3, Pages 335–341
52. **Impact of weight loss on survival after chemoradiation for locally advanced head and neck cancer: secondary results of a randomized phase III trial (SAKK 10/94).**  
Pirus Ghadjar, Stefanie Hayoz, Frank Zimmermann, Stephan Bodis, David Kaul, Harun Badakhshi, Jacques Bernier, Gabriela Studer, Ludwig Plasswilm, Volker Budach, Daniel M. Aebbersold, Swiss Group for Clinical Cancer Research (SAKK)  
Radiation oncology (London, England)  
Published on 01 Jan 2015 , doi:10.1186/s13014-014-0319-y



## 2014

51. **Could hyperthermia with proton mimic carbon ion therapy? Exploring a thermo-radiobiological rationale.**  
(N.R. Datta, E. Puric, R. Schneider, D. Weber, S. Rogers, S. Bodis)  
Int J Hyperthermia 2014; 30(7):524-530.
50. **In reply to Sharma et al**  
(N.R. Datta, M. Samiei, S. Bodis)  
Int J Radiat Oncol Biol Phys, 2014; 90: 971-972.
49. **Radiotherapy infrastructure and human resources in Europe – present status and its implications for 2020**  
(N.R. Datta, M. Samiei, S. Bodis)  
Europ J Cancer, 2014; 50: 2735-2743
48. **Radiation therapy infrastructure and human resources in low- and middle-income countries: present status and projections for 2020.**  
(N.R. Datta, M. Samiei, S. Bodis)  
Int J Radiat Oncol Biol Phys, 2014; Volume 50, Issue 15, Pages 2735–2743
47. **HYPROSAR: hyperthermia and proton radiotherapy in soft tissue sarcoma**  
N.R. Datta, E. Puric, R. Schneider, B. Fuchs, S. Bodis, D. Weber  
Leading Opinions in Oncology 2014; 2: 158-160.
46. **HYPERTHERMIA: its role in soft tissue sarcomas and recurrent breast carcinomas**  
(N.R. Datta, E. Puric, S. Bodis)  
Info@Onkologie, 2014; 4: 34-36.
45. **Tele-radiotherapy network for low- and middle –income group countries for providing cost effective comprehensive radiotherapy care for cancer patients**  
(N.R. Datta, M. Heuser, M. Samiei, R. Shah, G. Lutters, S. Bodis) In: Al-Shanableh T., Dabaj F, editors. Proceedings of the 2nd international conference on e-health and telemedicine and international course on tele-pathology systems and applications, Istanbul, Turkey. ICEHTM; 2014, p121-30.
44. **Personalized radiation oncology: from “4 lines” to “4 dimensions**  
(N.R. Datta, S. Bodis)  
Schweizer Krebsbulletin 2014; 34 (1);20
- Bis 2012**
43. **Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase ii trial of the siwss group for clinical research (sakk 70/03)**  
(G. Pesce, D. Klingbiel, K. Ribl, A. Zouhair, R. von Moos, M. Schläppi, C. Caspar, N. Fischer, S. Anchisi, S. Peters, R. Cathomas, J. Bernhard, N. Kotrubczik, G. D’Addario, C. Pilop, D. Weber, S. Bodis, M. Pless, M. Mayer, R. Stupp)  
European Journal of Cancer 02/2012; 48(3): 377-84
42. **Postoperative proton radiotherapy for localized and locoregional breast cancer: potential for clinically relevant improvements?**  
(C. Ares, S. Khan, A. McArtain, J. Heuberger, G. Goitein, G. Gruber, G. Lutters, E. Hug, S. Bodis, A. Lomax);

41. **Multicenter phase ii trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (sakk 75/02)**  
(T. Ruhstaller, L. Widmer, J.C. Schuller, A. Roth, V. Hess, W. Mingrone, R. von Moos, M. Borner, B.C. Pestalozzi, S. Balmermajno, D. Köberle, L. Terraciano, A. Schnider, S. Bodis, R. Popescu, for the Swiss Group for Clinical Cancer Research (SAKK))  
Ann. Oncol. 20; 2009; 1522-28
40. **Individual versus standard quality of life assessment in a phase ii clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes**  
(K. Ribi, J. Bernhard, J.C. Schuller, W. Weder, S. Bodis, M. Jörger, D. Betticher, R.A. Schmid, R. Stupp, H.B. Ris, R.A. Stahel; for the Swiss Group for Clinical Cancer Research (SAKK).  
Lung Cancer. 09/2008; 61(3):398-404, Epub. 04/2008
39. **Long-term results of radiotherapy in patients with chronic palmo-plantar eczema or psoriasis**  
(M. Sumila, M. Notter, P. Itin, S. Bodis, G. Gruber)  
Strahlentherapie Onkologie 04/2008; 184(4):218-23
38. **Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma**  
(W. Weder, R.A. Stahel, J. Bernhard, S. Bodis, P. Vogt, P. Ballabeni, D. Lardinois, D. Betticher, R. Schmid, R. Stupp, H.B. Ris, M. Jermann, W. Mingrone, A.D. Roth, A. Spiliopoulos; Swiss Group for Clinical Cancer Research)  
Ann. Oncol. 07/200; 18(7):1196-202. Epub. 04/2007
37. **Intrapleural topical application of cisplatin with the surgical carrier vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma**  
(D. Lardinois, F.J. Jung, I. Opitz, K. Rentsch, C. Latkoczy, V. Vuong, Z. Varga, V. Rousson, D. Günther, S. Bodis, R. Stahel, W. Weder)  
J Thorac Cardiovasc. Surg. 03/2006; 131(3):697-703
36. **G2/m cell cycle checkpoint is functional in cervical cancer patients after initiation of external beam radiotherapy**  
(F. Cerciello, B. Hofstetter, S.A. Fatah, M. Zaghloul, B. Odermatt, S. Bodis, Z. Varga, M. Pruschy, I.F. Ciernik.)  
Int J Radiation Oncology Biol. Phys. 08/2005; 62(5):1390-8
35. **Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo**  
(B. Hofstetter, V. Vuong, A. Broggin-Tenzer, S. Bodis, I.F. Ciernik, D. Fabbro, M. Wartmann, G. Folkers, M. Pruschy)  
Clinical Cancer Research 02/2005; Volume 11, Issue 4, pp 1588-1596
34. **Molecular radiation biology/oncology**  
(H.P. Rodemann, M. Baumann, S. Bodis, E. Dikomey)  
Radiotherapy and Oncology 09/2000; 72(3):247-9.

33. **Profiling treatment-specific post-translational modifications in a complex proteome with subtractive substrate phage display**  
(A. Tenzer, B. Hofstetter, C. Sauser, S. Bodis, A.P. Schubiger, C. Bonny, M. Pruschy)  
Proteomics 09/2004; 4(9):2796-804
32. **Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma**  
(W. Weder, P. Kestenholz, C. Taverna, S. Bodis, D. Lardinois, M. Jerman, R.A. Stahel)  
J. Clin. Oncol. 09/2004; 22(17):3451-7
31. **Differential activation of the phosphatidylinositol 3'-kinase/akt survival pathway by ionizing radiation in tumor and primary endothelial cells**  
(D. Zingg, O. Riesterer, D. Fabbro, C. Glanzmann, S. Bodis, M. Pruschy)  
Cancer Research 08/2004; 64(15):5398-406
30. **Management and costs of treating lung cancer patients in a university hospital**  
(K.J. Dedes, T.D. Szucs, S. Bodis, M. Joerger, A. Lowy, E.W. Russi, H.C. Steinert, W. Weder, R.A. Stahel)  
Pharmacoeconomics 2004; 22(7):435-44
29. **Degradation of pkb/akt protein by inhibition of the vegf receptor/mtor pathway in endothelial cells**  
(O. Riesterer, D. Zingg, J. Hummerjohann, S. Bodis, M. Pruschy)  
Oncogene 06/2004; 23(26):4624-35
28. **Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the pi3k/akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy?**  
(O. Riesterer, A. Tenzer, D. Zingg, B. Hofstetter, V. Vuong, M. Pruschy, S. Bodis)  
Int. J. Radiat. Oncol. Biol. Phys. 02/2004; Volume 58, Issue 2, Pages 361–368
27. **Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation**  
(K. Hostanska, V. Vuong, S. Rocha, M.S. Soengas, C. Glanzmann, R. Saller, S. Bodis, M. Pruschy)  
Br J Cancer 06/2003; 88(11):1785-92
26. **Signal transduction inhibitors as radiosensitizers**  
(A. Tenzer, D. Zingg, O. Riesterer, V. Vuong, S. Bodis, M. Pruschy)  
Curr. Med. Chem. Anticancer Agents 11/2002; 2(6):727-42
25. **Role of radiotherapy in non-small cell lung cancer**  
(J. Heuberger, K. Schneider, S. Bodis)  
Praxis (Bern 1994) 08/2002; 91(33):1307-14
24. **Effect of vegf receptor inhibitor ptk787/zk222584 [correction of zk222548] combined with ionizing radiation on endothelial cells and tumour growth**  
(C. Hess, V. Vuong, I. Hegyi, O. Riesterer, J. Wood, D. Fabbro, C. Glanzmann, S. Bodis, M. Pruschy)  
Br. J. Cancer 12/2001; 85(12):2010-6
23. **The phosphatidylinositide 3'-kinase/akt survival pathway is a target for the anticancer and radiosensitizing agent pkc412, an inhibitor of protein kinase c**  
(A. Tenzer, D. Zingg, S. Rocha, B. Hemmings, D. Fabbro, C. Glanzmann, P.A.

Schubiger, S. Bodis, M. Pruschy)  
Cancer Research 11/2001; 61(22):8203-10

22. **Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase c-specific inhibitor pkc412**  
(K. Zaugg, S. Rocha, H. Resch, I. Hegyi, C. Oehler, C. Glanzmann, D. Fabbro, S. Bodis, M. Pruschy)  
Cancer Research 01/2001; 61(2):732-8
21. **Key targets for the execution of radiation-induced tumor cell apoptosis: the role of p53 and caspases**  
(M. Pruschy, S. Rocha, K. Zaugg, A. Tenzer, C. Hess, D.E. Fisher, C. Glanzmann, S. Bodis)  
Int. Journal Radiation Oncology Biol. Phys. 02/2001; Volume 49, Issue 2, Pages 561–567
20. **Protein kinase c inhibitor and irradiation-induced apoptosis: relevance of the cytochrome c-mediated caspase-9 death pathway**  
(S. Rocha, M.S. Soengas, S.W. Lowe, C. Glanzmann, D. Fabbro, K. Winterhalter, S. Bodis, M. Pruschy)  
Cell Growth and Differentiation 09/2000; 11(9):491-9
19. **Pkc412--a protein kinase inhibitor with a broad therapeutic potential**  
(D. Fabbro, S. Ruetz, S. Bodis, M. Pruschy, K. Csermak, A. Man, P. Campochiaro, J. Wood, T. O'Reilly, T. Meyer)  
Anticancer Drug Design 02/2000; 15(1):17-28
18. **Is there a role for molecular prognostic factors in the clinical management of ductal carcinoma in situ (dcis) of the breast?**  
(K. Zaugg, S. Bodis)  
Radiotherapy and Oncology 05/2000; 55(2):95-9
17. **Ceramide triggers p53-dependent apoptosis in genetically defined fibrosarcoma tumour cells**  
(M. Pruschy, H. Resch, Y.Q. Shi, N. Aalame, C. Glanzmann, S. Bodis)  
Br. J. Cancer 05/1999; 80(5-6):693-8
16. **E2f-1 has properties of a radiosensitizer and its regulation by cyclin a kinase is required for cell survival of fibrosarcoma cells lacking p53**  
(M. Pruschy, C. Wirbelauer, C. Glanzmann, S. Bodis, W. Krek)  
Cell Growth and Differentiation 03/1999; 10(3):141-6
15. **Distinct mathematical behavior of apoptotic versus non-apoptotic tumor cell death**  
(P.H. Hardenbergh, P. Hahnfeldt, L. Hlatky, C. Takemoto, A. Shimamura, G. McGill, C.Y. Fung, S. Bodis, D.E. Fisher)  
Int. J. Radiat. Oncol. Biol. Phys. 02/1999; 43(3):601-5
14. **Molecular mechanisms of radioresistance: applications for head and neck cancer**  
(M. Pruschy, S. Bodis)  
Zeitschrift für Medizinische Physik, 1998, 8, 119-123
13. **The proto-oncogene c-fos mediates apoptosis in murine t-lymphocytes induced by ionizing radiation and dexamethasone**  
(M. Pruschy, Y.Q. Shi, N.E. Crompton, J. Steinbach, A. Aguzzi, C. Glanzmann, S. Bodis)  
Biochem. Biophys. Res Commun. 12/1997; 241(2):519-24

12. **Clinical presentation and outcome in lymphocyte-predominant hodgkin's disease**  
(S. Bodis, M.D. Kraus, G. Pinkus, B. Silver, M.E. Kadin, G.P. Canellos, L.N. Shulman, N.J. Tarbell, P.M. Mauch)  
J. Clin. Oncol. 09/1997; 15(9):3060-6
11. **Highly conserved asparagine in the basic domain of myc is dispensable for dna binding, transformation, and apoptosis**  
(S. Bodis, T. Hemesath, D.E. Fisher)  
Biochem. Mol. Med. 04/1997; 60(2):102-7
10. **Extensive apoptosis in ductal carcinoma in situ of the breast**  
(S. Bodis, K.P. Siziopikou, S.J. Schnitt, J.R. Harris, D.E. Fisher)  
Cancer 05/1996; 77(9):1831-5
09. **P53 status and the efficacy of cancer therapy in vivo**  
(S.W. Lowe, S. Bodis, A. McClatchey, L. Remington, H.E. Ruley, D.E. Fisher, D.E. Housman, T. Jacks)  
Science 11/1994; 266(5186): Vol. 266, Issue 5186, pp. 807-810
08. **The prevention of radiosurgery-induced nausea and vomiting by ondansetron: evidence of a direct effect on the central nervous system chemoreceptor trigger zone**  
(S. Bodis, E. Alexander III, H. Kooy, J.S. Loeffler)  
Surgical Neurology 1994 Sep;42(3):249-52
07. **Second primary cancers in patients continuously disease-free from hodgkin's disease: a protective role for the spleen?**  
(P.Y. Dietrich, M. Henry-Amar, J.M. Cosset, S. Bodis, J. Bosq, M. Hayat)  
Blood 08/1994; 84(4):1209-15
06. **Histopathologic grading of nodular sclerosis hodgkin's disease. Lack of prognostic significance in 254 surgically staged patients**  
(J.L. Hess, S. Bodis, G. Pinkus, B. Silver, P. Mauch)  
Cancer 07/1994; 74(2):708-14
05. **Significantly reduced salivary nitric oxide levels in smokers**  
(S. Bodis, A. Haregewoin)  
Annals of Oncology 04/1994; 5(4):371-2
04. **Apoptosis and the prognostic significance of p53 mutation**  
(S.W. Lowe, S. Bodis, N. Bardeesy, A. McClatchey, L. Remington, H.E. Ruley, D.E. Fisher, T. Jacks, J. Pelletier, D.E. Housman)  
Cold Spring Harb. Symp. Quant. Biol. 1994; 59:419-26
03. **Evidence for the release and possible neural regulation of nitric oxide in human saliva**  
(S. Bodis, A. Haregewoin)  
Biochemical Biophysical Research Communications 07/1993; 194(1):347-50
02. **Late relapse in early-stage hodgkin's disease patients enrolled on european organization for research and treatment of cancer protocols**  
(S. Bodis, M. Henry-Amar, J. Bosq, J.M. Burgers, W.A. Mellink, P.Y. Dietrich, N. Dupouy, E.M. Noordijk, J.M. Raemaekers, J. Thomas, et al.)

01. **Acute myelogenous leukemia with t-cell features**  
(V. Ribrag, C. Bayle, P. Brault, S. Bodis, E. Magherini, M. Hayat)  
Bull Cancer 1992; 79(12):1165-71

---

**Other Publications (Non Peer Review, 2012 – today, selected)**

---

06. **Stellenwert der regionären Hypertherie in der Krebstherapie**  
E. Stutz, N.R. Datta, E. Puric, S. Bodis  
Schweizerisches Medizin-Forum, 2017;17 (47, 1-4)
05. **Hyperthermie in der Krebsbehandlung**  
E. Stutz, E. Puric, O. Timm, D. Marder, N.R. Datta, S. Bodis  
Pipette Swiss Laboratory Medicine (Nr. 6-2017)
04. **Radiation therapy for non-small cell cancer lung: Current concepts.**  
Datta N.R. Ordonez SG, Bodis S.. InfoOnkologie & Heamotologie 2015: 3; (in press).
03. **HYPROSAR: Hyperthermia and Proton Radiotherapy in Soft Tissue Sarcoma.**  
Datta N.R., Puric E, Schneider R, Fuchs B, Bodis S, Weber, D. Leading Opinions in  
Oncology 2014; 2: 158-160.
02. **2014 Hyperthermia: its role in soft tissue sarcomas and recurrent breast carcinomas.** Datta N.R., Puric E, Bodis S Info@Onkologie, 2014, 4;34-36.
01. **Personalized radiation oncology: From “4 lines” to “4 dimensions”**  
Datta N.R., Bodis S., Schweizer Krebsbulletin 2014: 34 (1);20

---

**Reviews, Guidelines and Bookchapters (2012 – today, selected)**

---

04. **ESHO 2015 Program and Abstract Book** (S. Bodis, Co-Editor)
03. **Proceedings of the 14th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology, June 2015**  
(M. Baumann, S. Bodis, R. Bristow, A. van der Kogel, J. Overgaard, H.P. Rodemann, B. Wouters)  
Volume 11: ISBN 3-9808819-8-9
02. **Proceedings of the 13th Wolfsberg Meeting on Molecular Radiation Biology/Oncology June 2013**  
(M. Baumann, S. Bodis, E. Dikomey, A. van der Kogel, J. Overgaard, H.P. Rodemann)  
Volume 10: ISBN 3-9808819-7-0
01. **Annual Congress of American Society for Radiation Oncology – Highlights from Radiation Oncology**  
Rogers S, Bodis S; Leading Opinions - Hämatologie & Onkologie 06/2012; 8-9